Oragenics (NYSEAMERICAN:OGEN) Trading Down 0.3% – Here’s Why

Oragenics, Inc. (NYSEAMERICAN:OGEN)’s share price dropped 0.3% during mid-day trading on Tuesday . The stock traded as low as $0.7839 and last traded at $0.8295. Approximately 74,417 shares changed hands during mid-day trading, a decline of 82% from the average daily volume of 421,599 shares. The stock had previously closed at $0.8317.

Oragenics Trading Down 0.3%

The stock has a market capitalization of $3.54 million, a PE ratio of -0.07 and a beta of 1.09. The business’s 50 day moving average is $0.80 and its 200 day moving average is $1.01.

Hedge Funds Weigh In On Oragenics

A number of large investors have recently bought and sold shares of OGEN. Clear Street LLC bought a new position in Oragenics in the 2nd quarter valued at $270,000. Bank of America Corp DE boosted its stake in shares of Oragenics by 7,374.0% during the second quarter. Bank of America Corp DE now owns 15,546 shares of the company’s stock valued at $59,000 after purchasing an additional 15,338 shares during the period. Sabby Management LLC purchased a new stake in shares of Oragenics during the third quarter valued at $77,000. DRW Securities LLC grew its holdings in shares of Oragenics by 82.4% in the fourth quarter. DRW Securities LLC now owns 112,709 shares of the company’s stock worth $88,000 after purchasing an additional 50,900 shares during the last quarter. Finally, XTX Topco Ltd purchased a new position in Oragenics in the 4th quarter worth about $26,000. Hedge funds and other institutional investors own 18.71% of the company’s stock.

About Oragenics

Oragenics, Inc is a clinical-stage biotechnology company focused on the research and development of novel anti-infective therapeutics targeting oral and mucosal diseases. Headquartered in Tampa, Florida, the company leverages proprietary technologies to address unmet needs in dental and oral healthcare, with an emphasis on innovative treatments that can improve patient outcomes and reduce reliance on traditional antibiotics.

The company’s lead product candidate, Oraprev™, is being developed as a pre-procedural rinse designed to reduce oral microbial load prior to dental procedures.